A STAT examination shows how AI-powered biotechs like Absci and Generate Biomedicines routinely aggrandize their AI ...

Generate Biomedicines is setting out to “program” medicine by almost instantaneously creating models of new proteins. Launched out of life sciences venture firm Flagship Pioneering ...

What are "indirect costs" for universities? Why are some young scientists looking at opportunities abroad? And why are AI ...

SOMERVILLE, Mass., Jan. 9, 2025 /PRNewswire/ -- Generate:Biomedicines ("Generate") today announced that Mike Nally, Chief Executive Officer, will provide an update on the company's platform ...

Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis. The wide-ranging deal, worth up to $1 ...

Fresh from a sizeable funding round that raised $370 million, artificial intelligence-based drug discovery firm Generate Biomedicines has just signed its first major partnering deal with Amgen.

Generate:Biomedicines makes long-term commitment to pioneer programmable biology at IQHQ’s Innovation Park, home to its cutting-edge CryoEM laboratory BOSTON--(BUSINESS WIRE)--IQHQ, Inc ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

"We are at the forefront of a biological revolution," said Mike Nally, CEO of Generate:Biomedicines. "Generative AI is enabling us to tackle some of the toughest challenges in drug discovery ...

4 Corporate Drive at IQHQ’s Innovation Park district. Courtesy of IQHQ Generate:Biomedicines makes long-term commitment to pioneer programmable biology at IQHQ’s Innovation Park, home to its ...

"We are at the forefront of a biological revolution," said Mike Nally, CEO of Generate:Biomedicines. "Generative AI is enabling us to tackle some of the toughest challenges in drug discovery, from ...